1
|
Damron TA, Ward WG and Stewart A:
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer
Data Base Report. Clin Orthop Relat Res. 459:40–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Poletajew S, Fus L and Wasiutyński A:
Current concepts on pathogenesis and biology of metastatic
osteosarcoma tumors. Ortop Traumatol Rehabil. 13:537–545. 2011.(In
English and Polish). View Article : Google Scholar : PubMed/NCBI
|
3
|
Gill J, Ahluwalia MK, Geller D and Gorlick
R: New targets and approaches in osteosarcoma. Pharmacol Ther.
137:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Guise TA, O'Keefe R, Randall RL and Terek
RM: Molecular biology and therapeutics in musculoskeletal oncology.
J Bone Joint Surg Am. 91:724–732. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Salah S and Toubasi S: Factors predicting
survival following complete surgical remission of pulmonary
metastasis in osteosarcoma. Mol Clin Oncol. 3:157–162.
2015.PubMed/NCBI
|
6
|
Stefanatos RK and Vidal M: Tumor invasion
and metastasis in Drosophila: a bold past, a bright future. J Genet
Genomics. 38:431–438. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Mareel M, Oliveira MJ and Madani I: Cancer
invasion and metastasis: interacting ecosystems. Virchows Arch.
454:599–622. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Watanabe H: Extracellular
matrix-regulation of cancer invasion and metastasis. Gan To Kagaku
Ryoho. 37:2058–2061. 2010.(In Japanese). PubMed/NCBI
|
10
|
Lin YM, Chang ZL, Liao YY, Chou MC and
Tang CH: IL-6 promotes ICAM-1 expression and cell motility in human
osteosarcoma. Cancer Lett. 328:135–143. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Willis AL, Sabeh F, Li XY and Weiss SJ:
Extracellular matrix determinants and the regulation of cancer cell
invasion stratagems. J Microsc. 251:250–260. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Polette M, Nawrocki-Raby B, Gilles C,
Clavel C and Birembaut P: Tumour invasion and matrix
metalloproteinases. Crit Rev Oncol Hematol. 49:179–186. 2004.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Moss LA Shuman, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899. 2012.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Lynch CC: Matrix metalloproteinases as
master regulators of the vicious cycle of bone metastasis. Bone.
48:44–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Halbersztadt A, Haloń A, Pajak J,
Robaczyński J, Rabczynski J and St Gabryś M: The role of matrix
metalloproteinases in tumor invasion and metastasis. Ginekol Pol.
77:63–71. 2006.(In Polish). PubMed/NCBI
|
17
|
Khasigov PZ, Podobed OV, Gracheva TS,
Salbiev KD, Grachev SV and Berezov TT: Role of matrix
metalloproteinases and their inhibitors in tumor invasion and
metastasis. Biochemistry (Mosc). 68:711–717. 2003. View Article : Google Scholar : PubMed/NCBI
|
18
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancerr Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar
|
19
|
Korpi JT, Hagström J, Lehtonen N,
Parkkinen J, Sorsa T, Salo T and Laitinen M: Expression of matrix
metalloproteinases-2, −8, −13, −26, and tissue inhibitors of
metalloproteinase-1 in human osteosarcoma. Surg Oncol. 20:e18–e22.
2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bjørnland K, Flatmark K, Pettersen S,
Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases
participate in osteosarcoma invasion. J Surg Res. 127:151–156.
2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Loukopoulos P, O'Brien T, Ghoddusi M,
Mungall BA and Robinson WF: Characterisation of three novel canine
osteosarcoma cell lines producing high levels of matrix
metalloproteinases. Res Vet Sci. 77:131–141. 2004. View Article : Google Scholar : PubMed/NCBI
|
22
|
Felx M, Guyot MC, Isler M, Turcotte RE,
Doyon J, Khatib AM, Leclerc S, Moreau A and Moldovan F:
Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving
the transcription factor NF-kappaB in human osteosarcoma. Clin Sci
(Lond). 110:645–654. 2006. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhang XX, Fu Z, Zhang Z, Miao C, Xu P,
Wang T, Yang L and Cheng S: Microcystin-LR promotes melanoma cell
invasion and enhances matrix metalloproteinase-2/-9 expression
mediated by NF-κB activation. Environ Sci Technol. 46:11319–11326.
2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ahmad A, Biersack B, Li Y, Kong D, Bao B,
Schobert R, Padhye SB and Sarkar FH: Targeted regulation of
PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their
derivatives: mechanistic details and biological implications for
cancer therapy. Anticancer Agents Med Chem. 13:1002–1013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Kuan YH, Huang FM, Li YC and Chang YC:
Proinflammatory activation of macrophages by bisphenol
A-glycidyl-methacrylate involved NF-κB activation via PI3K/Akt
pathway. Food Chem Toxicol. 50:4003–4009. 2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Shrivastava S, Jeengar MK, Reddy VS, Reddy
GB and Naidu VG: Anticancer effect of celastrol on human triple
negative breast cancer: possible involvement of oxidative stress,
mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Exp Mol
Pathol. 98:313–327. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Li PP, He W, Yuan PF, Song SS, Lu JT and
Wei W: Celastrol induces mitochondria-mediated apoptosis in
hepatocellular carcinoma Bel-7402 cells. Am J Chin Med. 43:137–148.
2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Mi C, Shi H, Ma J, Han LZ, Lee JJ and Jin
X: Celastrol induces the apoptosis of breast cancer cells and
inhibits their invasion via downregulation of MMP-9. Oncol Rep.
32:2527–2532. 2014.PubMed/NCBI
|
29
|
Zhao X, Gao S, Ren H, Huang H, Ji W and
Hao J: Inhibition of autophagy strengthens celastrol-induced
apoptosis in human pancreatic cancer in vitro and in vivo models.
Curr Mol Med. 14:555–563. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Sampo M, Koivikko M, Taskinen M, Kallio P,
Kivioja A, Tarkkanen M and Böhling T: Incidence, epidemiology and
treatment results of osteosarcoma in Finland - a nationwide
population-based study. Acta Oncol. 50:1206–1214. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
32
|
Dai X, Ma W, He X and Jha RK: Review of
therapeutic strategies for osteosarcoma, chondrosarcoma, and
Ewing's sarcoma. Med Sci Monit. 17:RA177–RA190. 2011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Ando K, Heymann MF, Stresing V, Mori K,
Rédini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Lamoureux F, Trichet V, Chipoy C,
Blanchard F, Gouin F and Redini F: Recent advances in the
management of osteosarcoma and forthcoming therapeutic strategies.
Expert Rev Anticancer Ther. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
35
|
Li Y, Liao Q, Li K, Zhong D, Weng X and Mi
M: Knockdown of endothelin A receptor expression inhibits
osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse
model. Mol Med Rep. 5:1391–1395. 2012.PubMed/NCBI
|
36
|
Kato H, Wakabayashi H, Naito Y, Kato S,
Nakagawa T, Matsumine A and Sudo A: Anti-tumor necrosis factor
therapy inhibits lung metastasis in an osteosarcoma cell line.
Oncology. 88:139–146. 2015.PubMed/NCBI
|
37
|
Daw NC, Chou AJ, Jaffe N, Rao BN, Billups
CA, Rodriguez-Galindo C, Meyers PA and Huh WW: Recurrent
osteosarcoma with a single pulmonary metastasis: a
multi-institutional review. Br J Cancer. 112:278–282. 2015.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Hou CH, Lin FL, Tong KB, Hou SM and Liu
JF: Transforming growth factor alpha promotes osteosarcoma
metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem
Pharmacol. 89:453–463. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
40
|
Allison AC, Cacabelos R, Lombardi VR,
Alvarez XA and Vigo C: Celastrol, a potent antioxidant and
anti-inflammatory drug, as a possible treatment for Alzheimer's
disease. Prog Neuropsychopharmacol Biol Psychiatry. 25:1341–1357.
2001. View Article : Google Scholar : PubMed/NCBI
|
41
|
Cleren C, Calingasan NY, Chen J and Beal
MF: Celastrol protects against MPTP- and 3-nitropropionic acid
induced neurotoxicity. J Neurochem. 94:995–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
42
|
Jung HW, Chung YS, Kim YS and Park YK:
Celastrol inhibits production of nitric oxide and proinflammatory
cytokines through MAPK signal transduction and NF-kappaB in
LPS-stimulated BV-2 microglial cells. Exp Mol Med. 39:715–721.
2007. View Article : Google Scholar : PubMed/NCBI
|
43
|
Yu X, Zhou X, Fu C, Wang Q, Nie T, Zou F,
Guo R, Liu H, Zhang B and Dai M: Celastrol induces apoptosis of
human osteosarcoma cells via the mitochondrial apoptotic pathway.
Oncol Rep. 34:1129–1136. 2015.PubMed/NCBI
|